A detailed history of Bellevue Group Ag transactions in Castle Biosciences Inc stock. As of the latest transaction made, Bellevue Group Ag holds 1,262,030 shares of CSTL stock, worth $34.7 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
1,262,030
Previous 1,217,101 3.69%
Holding current value
$34.7 Million
Previous $26.5 Million 35.84%
% of portfolio
0.61%
Previous 0.44%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.4 - $31.47 $781,764 - $1.41 Million
44,929 Added 3.69%
1,262,030 $36 Million
Q2 2024

Aug 14, 2024

SELL
$18.84 - $24.94 $56,218 - $74,420
-2,984 Reduced 0.24%
1,217,101 $26.5 Million
Q1 2024

May 15, 2024

SELL
$18.06 - $25.3 $222,011 - $311,012
-12,293 Reduced 1.0%
1,220,085 $27 Million
Q4 2023

Feb 14, 2024

BUY
$12.19 - $22.43 $52,989 - $97,503
4,347 Added 0.35%
1,232,378 $26.6 Million
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $1.38 Million - $2.11 Million
103,988 Added 9.25%
1,228,031 $20.7 Million
Q2 2023

Aug 14, 2023

BUY
$11.66 - $26.0 $2.04 Million - $4.55 Million
175,165 Added 18.46%
1,124,043 $15.4 Million
Q1 2023

May 15, 2023

BUY
$19.47 - $28.49 $88,900 - $130,085
4,566 Added 0.48%
948,878 $21.6 Million
Q4 2022

Feb 14, 2023

BUY
$18.08 - $30.0 $44,133 - $73,230
2,441 Added 0.26%
944,312 $22.2 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $18,278 - $27,867
812 Added 0.09%
941,871 $24.6 Million
Q2 2022

Aug 11, 2022

BUY
$16.0 - $45.99 $5.34 Million - $15.3 Million
333,445 Added 54.88%
941,059 $20.7 Million
Q1 2022

May 13, 2022

BUY
$33.17 - $46.98 $20.2 Million - $28.5 Million
607,614 New
607,614 $27.3 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $723M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.